{"preliminary_commentary":{"by_channel":{"x_thread":12,"youtube":3,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06394570\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-31T10:12:00.530Z","note":"Automated from the 11 newest of 16 indexed sources (Jul 2024 – Sep 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":11,"text":"- Whether EV and radiation can support bladder-preserving approaches\n- Whether EV and radiation can increase pathologic complete response rates\n- How tolerable EV and radiation are together"},"drugs_tested":[["enfortumab vedotin"]],"indication":"localized bladder cancer","name":"STAR-EV","nct_id":"NCT06394570","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=star-ev-nct06394570. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"STAR-EV","arms":[{"description":"Neoadjuvant therapy of Enfortumab Vedotin 1.25 mg/kg (3 cycles) and sequential Radiation Therapy starting on Cycle 3 Day 21 of EV treatment (32.5 Gray in 5 fractions)","label":"Dose Level 0","type":"EXPERIMENTAL"},{"description":"Neoadjuvant therapy of Enfortumab Vedotin 1.25 mg/kg (3 cycles) and concurrent Radiation Therapy starting on Cycle 2 Day 15 of EV treatment (32.5 Gray in 5 fractions)","label":"Dose Level 1","type":"EXPERIMENTAL"},{"description":"Neoadjuvant therapy of Enfortumab Vedotin 1.25 mg/kg (3 cycles) and concurrent Radiation Therapy starting on Cycle 1 Day 15 of EV treatment (32.5 Gray in 5 fractions)","label":"Dose Level 2","type":"EXPERIMENTAL"}],"collaborators":["Astellas Pharma Inc"],"completion_date":{"date":"2029-09-30","type":"ESTIMATED"},"conditions":["Bladder Cancer"],"enrollment":{"count":19,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Enfortumab vedotin","otherNames":["PADCEV"],"type":"DRUG"}],"last_update":"2026-09-30","lead_sponsor":"University of Texas Southwestern Medical Center","official_title":"Stereotactic Treatment With neoAdjuvant Radiotherapy and Enfortumab Vedotin: a Phase I/II Study With Safety Lead-In for Localized Bladder Cancer (STAR-EV)","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2028-09-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Maximum Tolerated Dose (MTD) Regimen","timeFrame":"From initiation of Enfortuman Vedotin treatment until post neoadjuvant therapy visit (approximately 120 days)"},{"measure":"Pathologic Complete response rate at radical cystectomy","timeFrame":"At radical cystectomy following completion of neoadjuvant therapy (approximately 6 weeks after completion of EV treatment)"}],"references":[],"start_date":{"date":"2024-09-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT06394570"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/star-ev-nct06394570"}